Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
Kimberly-Clark closed its acquisition of Kenvue on November 2, absorbing the maker of Tylenol and Listerine to form a global consumer health and wellness business. The deal, valued between $40 billion and $49 billion, results in Kenvue stock being delisted from the NYSE. Kimberly-Clark has integrated former Kenvue executives into its leadership and launched a $3.1 billion integration program scheduled to run through 2029. The company aims to use the merger to improve overall growth and earnings.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Kimberly-Clark completed its acquisition of Kenvue on November 2.
- ✓ Kenvue is the manufacturer of Tylenol and Listerine.
- ✓ Kenvue stock will be delisted from the New York Stock Exchange.
- ✓ Former Kenvue executives have joined Kimberly-Clark.
What changed
Kimberly-Clark officially closed the Kenvue acquisition on November 2 and initiated a multi-year integration program.
Live updates
-
Kimberly-Clark Completes Acquisition of Kenvue
Kimberly-Clark closed its acquisition of Kenvue on November 2, absorbing the maker of Tylenol and Listerine to form a global consumer health and wellness business. The deal, valued between $40 billion and $49 billion, results in Kenvue stock being delisted from the NYSE. Kimberly-Clark has integrated former Kenvue executives into its leadership and launched a $3.1 billion integration program scheduled to run through 2029. The company aims to use the merger to improve overall growth and earnings.
Why it matters
This merger combines Kimberly-Clark's existing portfolio with Kenvue's healthcare brands. The acquisition occurs while a lawsuit in Texas regarding acetaminophen is ongoing.
What is confirmed
- Kimberly-Clark completed its acquisition of Kenvue on November 2.
- Kenvue is the manufacturer of Tylenol and Listerine.
- Kenvue stock will be delisted from the New York Stock Exchange.
- Former Kenvue executives have joined Kimberly-Clark.
- Kimberly-Clark started a $3.1 billion integration program that continues through 2029.
Still unconfirmed
- The deal value was estimated at almost $49 billion.
- The transaction was a cash-and-stock deal valued at about $48.7 billion.
- The merger value exceeded $40 billion.
What to watch next
- Kimberly-Clark earnings report on November 5
- Developments in the Texas lawsuit over acetaminophen
confidence 90%Sources used for this update (12)
- www.cnbc.com — Oil today: Iran, US, crude, wti, brent, trump
- CNBC — Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- PR Newswire — Kimberly-Clark Completes Acquisition of Kenvue, Creating the Preeminent Global Consumer Health and Wellness Leader
- GuruFocus — Kenvue (KVUE) Completes $40B+ Merger with Kimberly-Clark, Stock to Be Delisted from NYSE
- The Motley Fool — Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.
- TradingView — Kenvue Announced Transfer or Voluntary Withdrawal of Listing
- www.cnbc.com — Kimberly-Clark closes its acquisition of Tylenol maker Kenvue ...
- www.fool.com — Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to ...
- www.credenceresearch.com — Kimberly-Clark Closes Kenvue Acquisition, Starts $3.1 Billion ...
- www.prnewswire.com — Kimberly-Clark Completes Acquisition of Kenvue, Creating the ...
- startupfortune.com — Kimberly-Clark Agrees to Buy Tylenol Maker Kenvue for $48.7 ...
- finance.yahoo.com — Kimberly Clark (KMB) Completes Kenvue Acquisition
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community